Related Experiment Video
Updated: Sep 21, 2025
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity
Yiming Xu1, Yulong Xu2, Hallie Blevins1
1Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Researchers developed a novel small molecule inhibitor, compound 19, targeting the NLRP3 inflammasome for potential treatment of neurodegenerative disorders. This inhibitor shows enhanced potency, selectivity, and brain penetration, encouraging further disease model studies.
Area of Science:
- Biochemistry
- Pharmacology
- Neuroscience
Background:
- Dysregulation of the NLRP3 inflammasome is implicated in numerous human diseases, particularly neurodegenerative disorders.
- Targeting the NLRP3 inflammasome with small molecule inhibitors offers a promising therapeutic strategy for disease intervention.
Purpose of the Study:
- To optimize a lead inhibitor (YQ128) for enhanced potency and selectivity against the NLRP3 inflammasome.
- To identify novel inhibitors with improved pharmacological properties for potential therapeutic applications.
Main Methods:
- Structure-activity relationship (SAR) studies were conducted on a lead compound to guide optimization.
- A new lead inhibitor, compound 19, was synthesized and characterized.
- In vivo studies using wild-type and nlrp3 knockout mice assessed target engagement.
- Positron Emission Tomography (PET) studies evaluated brain penetration.
Main Results:
- Compound 19 demonstrated significantly improved potency (IC50: 0.12 ± 0.01 μM) and binding affinity (KD: 84 nM) compared to previous compounds.
- In vivo characterization confirmed selective target engagement of compound 19.
- PET imaging revealed enhanced brain penetration of a radiotracer based on compound 19.
Conclusions:
- Compound 19 represents a highly promising NLRP3 inflammasome inhibitor with favorable potency, selectivity, and brain penetration.
- These findings support further preclinical evaluation of compound 19 in relevant disease models.
More Related Videos
10:24NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
Published on: June 30, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...